Considerations for Ligand Binding Assay Platforms: how to choose the right platform to meet your drug development needs
Bioanalytical assays are essential in drug development. In recent years, many new technologies have emerged which offer scientists throughput, sensitivity, multiplexing, and the ability to better understand the data. Given the abundance of new platforms available to meet the most cumbersome and challenging of assays, it is difficult to determine the appropriate applications for these new technologies. In this presentation, we will provide an overview of platforms, case studies, and an evaluation of various new platforms.
What will you learn?
- Understand the differences in platform options in bioanalytical analysis
- How platforms are designed specifically to meet your performance needs and demands
- Discuss the Pros and Cons of available platforms
- Overview of new technologies
- Review case studies
Who should attend?
- Bioanalytical and Biomarker industry leaders
- Executives
- R&D
- Directors
- Outsourcing
- CRO
- Biotech and Pharmaceutical Industry
Speakers
Vimal Patel, MBA
Scientific Director
Eurofins Bioanalytical Services
Mr. Patel serves as Eurofins Scientific Director and consults on development, validation, and application of assays to ensure compliance with scientific and technical goals and regulatory requirements. Prior to joining Eurofins, Vimal worked for Amgen as a Scientist specializing in assay development, automation, new technologies and the application of Design of Experimentation to improve method transfer and validation. Mr. Patel received his BSc from Cal State University and his MBA from California Lutheran University and has served in leadership positions in various industry organizations, and as an invited speaker at multiple industry events.
For a full list of other webinars available on Bioanalysis Zone please see here.